Mind Medicine reports Q4 EPS (41c), consensus (28c)

Reports Cash and Cash Equivalents. As of December 31, 2024, MindMed had cash and cash equivalents totaling $273.7 million compared to $99.7 million as of December 31, 2023. The Company believes that its cash and cash equivalents as of December 31, 2024, will be sufficient to fund the Company’s operations into 2027. Based on the Company’s current operating plan and anticipated R&D milestones, the Company expects its cash runway to extend at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD.